THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS INSULIN-SECRETAGOGUES (SULPHONYLUREAS) OR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS AN ADD-ON TO METFORMIN IN IRELAND

被引：1
|
作者：
Bacon, T. [1 ]
Willis, M. [2 ]
Johansen, P. [2 ]
Neslusan, C. [3 ]
Nuhoho, S. [4 ]
Worbes-Cerezo, M. [5 ]
机构：
[1] Janssen Cilag Ltd, Dublin, Ireland
[2] Swedish Inst Hlth Econ, Lund, Sweden
[3] Janssen Global Serv LLC, Raritan, NJ USA
[4] Janssen Cilag AS, Birkerod, Denmark
[5] Janssen Cilag UK, High Wycombe, Bucks, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.704
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB81
引用
收藏
页码：A346 / A346
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
    Pititto, L.
    Neslusan, C.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    Asano, E.
    Puig, A.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
  • [2] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [3] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    [J]. DIABETES, 2014, 63 : A310 - A310
  • [4] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)
    Fonseca, Vivian
    Dejager, Sylvie
    Albrecht, Diego
    Shirt, Lynda
    Schweizer, Anja
    [J]. DIABETES, 2006, 55 : A111 - A111
  • [5] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (T2DM) FAILING TO ACHIEVE GLYCAEMIC CONTROL ON METFORMIN MONOTHERAPY IN IRELAND
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Nuhoho, S.
    Worbes-Cerezo, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A345 - A345
  • [6] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [7] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [8] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
    Shafie, Asrul Akmal
    Ng, Chin Hui
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
  • [9] Cost-Effectiveness Analysis of Canagliflozin (CANA) vs. Maximally Titrated Glimepiride (GLIM) as an Add-on to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM) in the United States
    Neslusan, Cheryl
    Martin, Silas
    Teschemaker, Anna
    Vo, Lien
    Johansen, Pierre
    Willis, Michael
    [J]. DIABETES, 2014, 63 : A309 - A310
  • [10] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
12345